June 22, 2018, Gmax Biopharm, a clinical stage biopharmaceutical company focusing on therapeutic antibody development targeting GPCRs, announced today that it will present the recent clinical progresses of its GLP-1R antibody Glutazumab at the coming 78th American Diabetes Association Scientific Sessions. The 78th ADA Scientific Sessions will take place in Orlando, June 22-26, 2018.

Abstract – 2298-PUB: A phase 1b/2a study of Glutazumab for the treatment of type 2 diabetes and obesity